Results 41 to 50 of about 663,256 (217)

Progression-free survival in the ICON8 trial [PDF]

The Lancet, 2020
Alexandre Andre, Balieiro Anastacio da Costa, Glauco, Baiocchi, Andrea Paiva Gadelha, Guimarães   +2 more
openaire   +4 more sources

Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study

BMC Cancer, 2020
Background The purpose of this study was to assess the efficacy and safety of cisplatin-based chemotherapy with or without bevacizumab (BEV) in Chinese women with advanced cervical cancer (ACC).
Xiaoli He, Jun Liu, Li Xiao, Mingdong Zhao, Tingting Su, Tiejian Liu, Guowei Han, Yue Wang   +7 more
doaj   +1 more source

Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival [PDF]

JNCI: Journal of the National Cancer Institute, 2009
Whether progression-free survival (PFS) or overall survival (OS) is the more appropriate endpoint in clinical trials of metastatic cancer is controversial. In some disease and treatment settings, an improvement in PFS does not result in an improved OS.We partitioned OS into two parts and expressed it as the sum of PFS and survival postprogression (SPP).
Kristine R, Broglio, Donald A, Berry
openaire   +2 more sources

Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial

Current Oncology
Background: A single measurement or a summary of a limited number of measurements of CA125 was considered in the prediction of clinical outcomes for patients with ovarian cancer.
Chang Yin, Josee-Lyne Ethier, Mark S. Carey, Dongsheng Tu, Xueying Zheng   +4 more
doaj   +1 more source

Diagnostic characteristics, treatment outcomes, and prognostic factors in glucagonomas

Endocrine Oncology
Objective: Glucagonomas are rare islet cell tumours, accounting for 2% of such tumours, with an annual incidence of 0.01–0.1 per million. This study aimed to describe diagnostic characteristics and treatment outcomes in patients with glucagonoma from a ...
Eleni Armeni, Alexander Branton, Juliana Porto, Dalvinder Mandair, Aimee R Hayes, Aspasia Manta, Shaunak Navalkissoor, Gopinath Gnanasegaran, Ann-Marie Quigley, Ashley B Grossman, Martyn Caplin, Christos Toumpanakis   +11 more
doaj   +1 more source

PF389 PROGRESSION‐FREE SURVIVAL PREDICTS OVERALL SURVIVAL IN FRONTLINE CLL

HemaSphere, 2019
Background:Many phase II and III trials in oncology utilise the surrogate endpoint progression‐free survival (PFS) as the primary endpoint; however, the relationship between a surrogate endpoint and true clinical benefit in terms of overall survival (OS) or quality of life must be demonstrated.Aims:This research aimed to explore and quantify the ...
S. Baculea, S. Horsburgh, S. Chadda, L. Nelson, C. LeReun   +4 more
openaire   +1 more source

Prognostic Factors of Atypical Meningioma : Overall Survival Rate and Progression Free Survival Rate [PDF]

Journal of Korean Neurosurgical Society, 2017
Atypical meningioma is rare tumor and there is no accurate guide line for optimal treatment. This retrospective study analyzed the prognostic factors, the effect of different methods of treatments and the behavior of atypical meningioma.Thirty six patients were diagnosed as atypical meningioma, among 273 patients who were given a diagnosis of ...
Lee, Jae Ho, Kim, Oh Lyong, Seo, Young Beom, Choi, Jun Hyuk   +3 more
openaire   +2 more sources

NSCLC Patients Achieving Long-term Progression-free Survival With Docetaxel Plus Ramucirumab: A Retrospective Study [PDF]

, 2023
Kunihiko Miyazaki, Toshihiro Shiozawa, Shinichiro Okauchi, Hirofumi Sakurai, Hiroaki Satoh, Nobuyuki Hizawa   +5 more
openalex   +1 more source

Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands

Health and Quality of Life Outcomes, 2012
Background Gefitinib, a tyrosine kinase inhibitor, is an effective treatment in advanced non-small cell lung cancer (NSCLC) patients with an activating mutation in the epidermal growth factor receptor (EGFR).
Verduyn S, Biesma Bonne, Schramel Franz MNH, van der Scheer Feike W, Langenfeld Merel K, de Peuter Maria A, Dingemans Anne-Marie C   +6 more
doaj   +1 more source

The role of Lobectomy in Glioblastoma management: A Retrospective series

Brain and Spine
Introduction: Treatment choices for glioblastoma (GB) remain scarce. Multiple clinical studies have demonstrated the importance of supramaximal resection.
Christina K. Arvaniti, Alexandros G. Brotis, Jacob S. Young, Sivani Sivanrupan, Gracia Menna, Masahiro Nishide, Philippe Schucht, Mitchel Berger, Kostas N. Fountas   +8 more
doaj   +1 more source